Aspiring Danish biotech concludes collaboration with Sanofi
The so far most important collaboration agreement in the Danish biotech company Gubra’s history has come to an end and the CEO looks back on a partnership that has placed the company in a strong position in a new, attractive field.
BY ELIZABETH MØNSTED JOHANSEN
After four years with Sanofi, it is time to say goodbye for the Danish biotech company Gubra.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Biotech and CRO outfit Gubra continues explosive growth
For abonnenter
Danish CRO reaches milestone in Sanofi deal
For abonnenter
Danish company signs pact with Sanofi
For abonnenter
.jpg&w=384&q=75)
